Form 4: Charles River Laboratories Director Acquires Equity Through Compensation Plan

Abraham Ceesay, a Director at Charles River Laboratories International, Inc., acquired 946 shares of common stock and 2,082 stock options on June 2, 2025, as part of a pre-arranged Rule 10b5-1 plan.

Summary

• Abraham Ceesay, a Director of Charles River Laboratories International, Inc. (CRL), acquired 946 shares of common stock and 2,082 stock options.
• The transaction occurred on June 2, 2025, and was executed pursuant to a Rule 10b5-1(c) plan, indicating a pre-scheduled transaction.
• The 946 shares of common stock are unvested restricted stock units (RSUs) acquired at a price of $135.04 per share.
• These RSUs will vest upon the earlier of June 2, 2026, or the business day prior to the Company's next annual meeting of shareholders.
• The 2,082 stock options have an exercise price of $135.04 per share and become exercisable upon the earlier of June 2, 2026, or the business day prior to the Company's next annual meeting of shareholders.
• The stock options have an expiration date of June 2, 2035.
• Following these transactions, Abraham Ceesay beneficially owns 946 shares of common stock directly and 2,082 stock options directly.

Sentiment

Score: 7

Explanation: A director's acquisition of company equity, including restricted stock units and stock options, generally signals confidence in the company's future prospects and aligns management interests with shareholders. This is a positive signal, though it's a routine compensation event rather than a discretionary open market purchase.

Positives

• The acquisition of equity by a director aligns their financial interests with those of the shareholders, potentially signaling confidence in the company's future performance.
• The transaction was conducted under a Rule 10b5-1 plan, which provides a defense against insider trading allegations by pre-scheduling trades, indicating a structured approach to equity compensation.

Future Outlook

NA

Industry Context

This Form 4 filing is a routine disclosure of an insider's equity compensation and does not provide broader industry context or trends. It reflects standard practices for executive and director compensation in publicly traded companies, particularly within the life sciences and pharmaceutical services sector where Charles River Laboratories operates.

Stakeholder Impact

• Shareholders: The acquisition of equity by a director increases their personal stake in the company's performance, aligning their interests more closely with those of shareholders and potentially fostering long-term value creation.

Next Steps

• Vesting of 946 restricted stock units upon the earlier of June 2, 2026, or the business day prior to the Company's next annual meeting of shareholders.
• Stock options becoming exercisable upon the earlier of June 2, 2026, or the business day prior to the Company's next annual meeting of shareholders.

Key Dates

Keywords

Charles River Laboratories, CRL, SEC Form 4, Insider Transaction, Stock Acquisition, Stock Options, Restricted Stock Units, Director Compensation, Equity Compensation, Rule 10b5-1